Last reviewed · How we verify

NCT06936475

Vaginal Cleansing With Chlorhexidine Versus Iodine for Prevention of Endometritis

Completed NA Last updated 1 May 2025
What this trial tests

NA trial testing Povidone-Iodine in Endometritis in 239 participants. Completed in 14 September 2020.

Timeline
1 June 2020
Primary endpoint
14 September 2020
14 September 2020

Quick facts

Lead sponsorFederal Teaching Hospital Abakaliki
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposesupportive care
Enrollment239
Start date1 June 2020
Primary completion14 September 2020
Estimated completion14 September 2020
Sites1 location across Nigeria

Drugs / interventions tested

Conditions studied

Sponsor

Federal Teaching Hospital Abakaliki

Who can join

Adults 15 to 45, female only, with Endometritis or Vaginal Cleansing. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Povidone has been approved for vaginal cleansing in the prevention of endometritis postcaesarean section. chlorhexidine solution which is cheap and readily available as shown to prevent endometritis.The aim of this study is to compare the effectiveness of post-operative vaginal cleansing with povidone-iodine versus chlorhexidinegluconate in reducing post-caesarean maternal endometritis

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Povidone-Iodine

Trials testing the same drug.

Other recruiting trials for Endometritis

Currently open trials in the same condition.

Other Federal Teaching Hospital Abakaliki trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06936475.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing